Premium
Allogeneic bone marrow transplantation in 24 patients with multiple myeloma reported to the ebmt registry
Author(s) -
Gahrton G.,
Tura S.,
Flesch M.,
Gratwohl A.,
Gravett P.,
Lindeberg A.,
Lucarelli G.,
Michallet M.,
Reiffers J.,
Ringdén O.,
Nikoskelainen J.,
Van Lint M. T.,
Vernant J.P.,
Zwaan F. E.
Publication year - 1988
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2900060219
Subject(s) - medicine , multiple myeloma , bone marrow , transplantation , bone marrow transplantation , surgery , gastroenterology
Twenty‐four patients with multiple myeloma received an allogeneic bone‐marrow graft from HLA‐compatible sibling donors ( n = 23), or a twin donor ( n = 1). Eighteen patients are alive, 1‐36 months post bone‐marrow transplantation (median 14 months). Ten of these patients had no signs of multiple myeloma as judged by immunoglobulins in serum, light chains in urine, or the percentage of plasma‐cells in bone‐marrow aspirate. Bone lesions on X‐ray were mainly unchanged. Six patients died from transplant‐related complications 3 weeks to 5 months post transplantation. One of these patients had severe acute graft‐versus‐host disease (aGVHD). In other patients aGVHD was a minor problem. Allogeneic bone‐marrow transplantation appears to be a promising method for treatment of a selected group of patients with multiple myeloma.